KR100894359B1 - 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법 - Google Patents

포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법 Download PDF

Info

Publication number
KR100894359B1
KR100894359B1 KR1020027003089A KR20027003089A KR100894359B1 KR 100894359 B1 KR100894359 B1 KR 100894359B1 KR 1020027003089 A KR1020027003089 A KR 1020027003089A KR 20027003089 A KR20027003089 A KR 20027003089A KR 100894359 B1 KR100894359 B1 KR 100894359B1
Authority
KR
South Korea
Prior art keywords
polypeptide
cells
fab
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027003089A
Other languages
English (en)
Korean (ko)
Other versions
KR20020034185A (ko
Inventor
옵맨버짓
드발말레피트르느
렌닉도나엠.
카스텔레인로버트에이.
비에코우스키마리아티.
리라세르지오에이.
나눌라샛원트케이.
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26860707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100894359(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20020034185A publication Critical patent/KR20020034185A/ko
Application granted granted Critical
Publication of KR100894359B1 publication Critical patent/KR100894359B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
KR1020027003089A 1999-09-09 2000-09-08 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법 Expired - Lifetime KR100894359B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US09/393,090 1999-09-09
US16461699P 1999-11-10 1999-11-10
US60/164,616 1999-11-10

Publications (2)

Publication Number Publication Date
KR20020034185A KR20020034185A (ko) 2002-05-08
KR100894359B1 true KR100894359B1 (ko) 2009-04-22

Family

ID=26860707

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027003089A Expired - Lifetime KR100894359B1 (ko) 1999-09-09 2000-09-08 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법

Country Status (15)

Country Link
EP (1) EP1210434B2 (https=)
JP (6) JP4505166B2 (https=)
KR (1) KR100894359B1 (https=)
CN (1) CN100529076C (https=)
AR (1) AR035560A1 (https=)
AT (1) ATE389019T1 (https=)
AU (2) AU780163B2 (https=)
CA (1) CA2388562C (https=)
DE (1) DE60038304T3 (https=)
ES (1) ES2300276T5 (https=)
HK (1) HK1044170B (https=)
HU (1) HU230679B1 (https=)
IL (1) IL148300A0 (https=)
MX (1) MXPA02002684A (https=)
WO (1) WO2001018051A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JPWO2009133863A1 (ja) * 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034249T2 (de) * 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
ZA986596B (en) * 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
WO1999040195A1 (en) * 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor

Also Published As

Publication number Publication date
JP6140122B2 (ja) 2017-05-31
JP2003510038A (ja) 2003-03-18
HUP0301102A2 (hu) 2003-07-28
JP2010233571A (ja) 2010-10-21
HUP0301102A3 (en) 2005-11-28
EP1210434B1 (en) 2008-03-12
HU230679B1 (en) 2017-08-28
CN100529076C (zh) 2009-08-19
EP1210434B2 (en) 2016-12-14
JP2013128489A (ja) 2013-07-04
IL148300A0 (en) 2002-09-12
JP2015051005A (ja) 2015-03-19
ES2300276T5 (es) 2017-06-02
KR20020034185A (ko) 2002-05-08
JP2007045830A (ja) 2007-02-22
AU7360800A (en) 2001-04-10
AU2008240348B2 (en) 2012-07-12
DE60038304T2 (de) 2009-03-19
AR035560A1 (es) 2004-06-16
CN1387571A (zh) 2002-12-25
MXPA02002684A (es) 2002-07-30
HK1044170B (en) 2008-08-01
ES2300276T3 (es) 2008-06-16
JP4505166B2 (ja) 2010-07-21
JP4969610B2 (ja) 2012-07-04
DE60038304D1 (de) 2008-04-24
WO2001018051A3 (en) 2001-09-20
AU2008240348A1 (en) 2008-11-27
WO2001018051A2 (en) 2001-03-15
CA2388562C (en) 2014-07-22
AU780163B2 (en) 2005-03-03
ATE389019T1 (de) 2008-03-15
JP2009268467A (ja) 2009-11-19
CA2388562A1 (en) 2001-03-15
HK1044170A1 (en) 2002-10-11
EP1210434A2 (en) 2002-06-05
DE60038304T3 (de) 2017-04-06

Similar Documents

Publication Publication Date Title
KR100894359B1 (ko) 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
US7883695B2 (en) IL-12P40 and IL-B30 polypeptide complex
US7608690B2 (en) IL-B30 antibodies
DK2100959T3 (en) Mammalian cytokine: Interleukin-B30 and associated reagents
JP2003500010A (ja) 哺乳動物サイトカイン；関連試薬および方法
AU2005202420B2 (en) Mammalian cytokines; related reagents and methods
CN101602807A (zh) 哺乳动物细胞因子、相关试剂和方法
HK1112754A (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1905832A2 (en) Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020308

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050906

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060929

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090414

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090414

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120329

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120329

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130329

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130329

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160328

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160328

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180330

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180330

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190329

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190329

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20210308

Termination category: Expiration of duration